Cut-off levels of NSE to differentiate SCLC from NSCLC

Oncology Reports

Volumn 9, Issue 3, 2002, Pages 581-583

  Satoh, Hiroaki ^a   Ishikawa, Hiroichi ^a   Kurishima, Koichi ^a   Yamashita, Yuko T ^b   Ohtsuka, Morio ^a   Sekizawa, Kiyohisa ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b UNIVERSITY HOSPITAL OF THE RYUKYUS   (Japan)

Author keywords

Neuron specific enolase; Nonsmall cell lung cancer; Small cell lung cancer

Indexed keywords

ENOLASE;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; BLOOD; CELL DIFFERENTIATION; CLINICAL CHEMISTRY; FEMALE; HUMAN; LABORATORY DIAGNOSIS; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METHODOLOGY; MIDDLE AGED; ROC CURVE; SENSITIVITY AND SPECIFICITY; SMALL CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CELL DIFFERENTIATION; CHEMISTRY, CLINICAL; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 0036581282     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.3.581     Document Type: Article

References (22)

1. World Health Organization: The World Health Organization histological typing of the lung tumors. Am J Clin Pathol 77: 123-136, 1982.
2. Carney DN, Marangos PJ, Ihde DC, Bunn PJ, Cohen H and Minna JD, Gazdar AF: Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet i: 583-585, 1982. (Pubitemid 12171820)
3. Burghuber OC, Worofka B, Schernthaner G, Vetter N, Neumann M, Dudczak R and Kuzmits R: Serum neuron-specific enolase is a useful tumor marker for small cell lung cancer. Cancer 65: 1386-1390, 1990. (Pubitemid 20097167)
4. Splinter TA, Cooper EH, Kho GS, Oosterom R and Peake MD and Kho GS: Neuron-specific enolase as a guide to the treatment of small cell lung cancer. Eur J Cancer Clin Oncol 23: 171-176, 1987. (Pubitemid 17229904)
5. Gomm SA, Keevil BG, Thatcher N, Hastleton PS and Swindell RS: The value of tumor markers in lung cancer. Br J Cancer 58: 797-804, 1988. (Pubitemid 19033399)
6. Jorgensen LG, Osterlind K, Hansen HH and Cooper EH: Serum neuron specific enolase (NSE) is a determinant of response duration in small cell lung cancer (SCLC). Br J Cancer 66: 594-598, 1992.
7. Quoix E, Charloux A, Popin E and Pauli G: Inability of serum neuron-specific enolase to predict disease extent in small cell lung cancer. Eur J Cancer 29A: 2248-2250, 1993. (Pubitemid 24053002)
8. Johnson PW, Joel SP, Love S, Butcher M, Pandian MR, Squires L, Wrigley PF and Slevin ML: Tumor markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer 67: 760-767, 1993.
9. Milleron B, Cadrenel J, Liote H, François T, Scarna H and Akoun G: Prognostic value of serum neuron-specific enolase (SNSE) in small-cell lung cancer (SCLC). Lung Cancer 4 (Suppl): A47, 1988.
10. Kozakai K, Takano M, Abe K, Tanaka N, Sato K, Maruyama Y, Noguchi M, Kaneko I, Sasaki Y and Tsujino D: Evaluation of neuronspecific enolase (NSE) radioimmunoassay kit. Kaku Igaku23: 85-91, 1986.
11. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111: 1710-1717, 1997.
12. Murren JR and Buzaid AC: Chemotherapy and radiation for the treatment of non-small cell lung cancer. Clin Chest Med 14: 161-171, 1993. (Pubitemid 23098995)
13. Evans WK, Shepherd FA, Feld R, Osoba D, Dang P and Deboer G: VP-16 and cisplatin as first-line therapy for smallcell lung cancer. J Clin Oncol 3: 1471-1477, 1985. (Pubitemid 16246758)
14. Lowenbraun S, Birch R, Buchanan R, Krauss S, Durant J, Perez C, Mill W, Vollmer R and Ogden L: Combination chemotherapy in small cell lung carcinoma. A randomized study of two intensive regimens. Cancer 54: 2344-2350, 1984. (Pubitemid 15223370)
15. Sandler AB and Buzaid AC: Lung cancer: a review of current therapeutic modalities. Lung 170: 249-265, 1992.
16. Ihde DC and Minna JD: Non-small cell lung cancer. Biology, diagnosis and staging. Curr Probl Cancer 15: 61-104, 1991.
17. Lombardi C, Tassi GF, Pizzocolo G and Donato F: Clinical significance of a multiple biomarker assay in patients with lung cancer: a study with logistic regression analysis. Chest 97: 639-644, 1990. (Pubitemid 20095584)
18. Pujol JL, Grenier J, Daurès JP, Daver A, Pujol H and Michel FB: Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1: immunoradiometric assay as a marker of lung cancer. Cancer Res 53: 61-66, 1993. (Pubitemid 23019377)
19. Buccheri GF, Ferrigno D, Sartoris AM, Violante B, Vola F and Curcio A: Tumor markers in bronchogenic carcinoma: superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9. Cancer 60: 42-50, 1987. (Pubitemid 17083549)
20. Anastasiades KD, Mullins RE and Conn RB: Neuron-specific enolase: assessment of ELISA in patients with small cell carcinoma of the lung. Am J Clin Pathol 87: 245-249, 1987. (Pubitemid 17022466)
21. Buccheri GF, Violante B, Sartoris AM, Ferrigno D, Curcio A and Vola F: Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma. Cancer 57: 2389-2396, 1986. (Pubitemid 16118981)
22. Goto K, Kodama T, Hojo F, Kubota K, Kakinuma R, Matsumoto T, Ohmatsu H, Sekine I, Nagai K and Nishiwaki Y: Clinicopathologic characteristics of patients with non-small cell lung carcinoma with elevated serum progastrin-releasing peptide levels. Cancer 82: 1056-1061, 1998. (Pubitemid 28136517)